Brief: Vir Biotechnology Announces Topline Data From Phase 2 Peninsula Trial Evaluating Vir-2482 For Prevention Of Seasonal Influenza A Illness
20/07/2023 14:15
July 20 (Reuters) - Vir Biotechnology Inc VIR.O :
* VIR BIOTECHNOLOGY ANNOUNCES TOPLINE DATA FROM PHASE 2
PENINSULA
TRIAL EVALUATING VIR-2482 FOR THE PREVENTION OF SEASONAL
INFLUENZA A ILLNESS
* VIR BIOTECHNOLOGY INC - VIR-2482 WAS GENERALLY WELL
TOLERATED
AND NO SAFETY SIGNALS WERE IDENTIFIED.
* VIR BIOTECHNOLOGY INC - WE EXPECT TWO DATA READOUTS ACROSS
OUR
HEPATITIS B AND HEPATITIS D PROGRAMS IN 2023
* VIR BIOTECHNOLOGY - PHASE 2 PENINSULA TRIAL EVALUATING
VIR-2482
FOR PREVENTION OF SYMPTOMATIC INFLUENZA A ILLNESS DID NOT MEET
PRIMARY/SECONDARY EFFICACY ENDPOINTS
* VIR BIOTECHNOLOGY INC - HAVE ABOUT $1.9 BILLION IN CASH
AND
INVESTMENTS, AS OF END OF Q2
Source text for Eikon: ID:nGNX6Y0nj7
Further company coverage: VIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO